

Richard Haynes

From: Kate O'Neill <kate.oneill@admin.ox.ac.uk>
Sent: 14 October 2022 17:10
To: Richard Haynes
Cc: Leon Peto; Joseph Butchinsky
Subject: RECOVERY SA29 - Sponsor approval
Attachments: 281712_Substantial Amendment 29_.pdf

Dear Professor Haynes,

Thank you for sending us the documents for the amendment to this study.

Please find attached the PDF version of the signed and locked amendment tool.

Please submit this signed amendment tool, together with the tracked and clean copies of all amendment documents, via the online amendment submission portal (for further guidance please refer to the HRA training video: [how to complete online submission of amendments](#)).

Please also send your submission to the MHRA via the [MHRA submission portal](#) (if you are not yet set up on this platform, please contact ctrig@admin.ox.ac.uk).

When you have received the submission confirmation, please email this, with the final documents you submitted, to ctrig@admin.ox.ac.uk.

Please send a copy of the approval letters to ctrig@admin.ox.ac.uk once you have received them. Please do not implement your amendment until all approvals are in place.

Do let me know if you have any questions, or need any further information.

Kind regards,

Kate



researchsupport.admin.ox.ac.uk

Dr Kate O'Neill

Regulatory and Quality Assurance Lead

Research Services | Research Governance, Ethics & Assurance Team

University of Oxford, Boundary Brook House, Churchill Drive, Headington, Oxford OX3 7GB

T: 01865 616488 E: kate.oneill@admin.ox.ac.uk

Normal working days Monday – Thursday



PID14892-A034-SP001-AC001

From: Richard Haynes <richard.haynes@ndph.ox.ac.uk>
Sent: 12 October 2022 08:11
To: CTRG Sponsorship Correspondence <ctrig@admin.ox.ac.uk>
Cc: Heather House <heather.house@admin.ox.ac.uk>; Leon Peto <leon.peto@ndph.ox.ac.uk>
Subject: RECOVERY substantial amendment

Hello

We have received the necessary documents to extend the shelf-life for our sotrovimab supply. I've attached the relevant paperwork. I will ask the OUH clinical trial pharmacy team to check the procedure that is described in our pharmacy manual, but we have done a similar process before so I think it should be similar.

If you have any comments please let me know, otherwise I'd be grateful if you could send your approval email in due course.

Many thanks for your help.

Best wishes

Richard

PS the amendment tool needs a new name for the sponsor's representative

Richard Haynes

Professor of Renal Medicine & Clinical Trials

Deputy Director | Medical Research Council Population Health Research Unit at the University of Oxford

Richard Doll Building, Old Road Campus,

Roosevelt Drive, Oxford OX3 7LF

richard.haynes@ndph.ox.ac.uk

+44 (0)1865 743607